29.49

2.16% -0.65

After Hours: 30.07 0.58 +1.97%

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is traded at $29.49, with a volume of 1.19M. It is down -2.16% in the last 24 hours and down -21.28% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Previous Close:

$30.14

Open:

$30.28

24h Volume:

1.19M

Relative Volume:

0.50

Market Cap:

$3.76B

Revenue:

$-665.00K

Net Income/Loss:

$-150.11M

P/E Ratio:

-19.57

EPS:

-1.5071

Net Cash Flow:

$-124.53M

1W Performance:

-9.01%

1M Performance:

-21.28%

6M Performance:

+113.23%

1Y Performance:

+113.39%

1-Day Range:

$29.47

$30.70

1-Week Range:

$29.47

$33.19

52-Week Range:

$10.83

$41.14

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

617-682-0917

Address

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Employee

136

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

AMLX's Discussions on Twitter

Compare AMLX vs TAK, TEVA, HLN, ZTS, VTRS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMLX Amylyx Pharmaceuticals Inc	29.49	3.76B	-665.00K	-150.11M	-124.53M	-1.5071
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-26	Initiated	Stifel	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Guggenheim	Buy
Jun-17-25	Initiated	Citigroup	Buy
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy
Mar-18-24	Downgrade	Mizuho	Buy → Neutral
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

09:22 AM